Stereotactic core biopsy of the breast: Results of one-year follow-up of 101 patients

Brian Pitre, Paul L. Baron, Lisa F. Baron, Paul H. O'Brien, David J. Cole

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Stereotactic core biopsy (SCB) is being used as a cost-effective alternative to needle localized biopsy (NLB). However, an area of concern is the potential for sampling error, with sparse surgical data available concerning follow-up and failure rates. We therefore reviewed our results in patients undergoing SCB for mammographically detected breast abnormalities. Between January 1994 and February 1995, 128 patients underwent SCB. Average age was 56.4 years. Nine patients (7.0%) had histologic evidence of malignancy, with 111 (86.7%) benign diagnoses requiring no further initial intervention. Eight patients (6.3%) proceeded directly to NLB, five because of technical failure of SCB and three because of suspicious initial histology. One of the latter patients had ductal carcinoma in situ. The remaining 111 SCB patients were evaluated at 6 months and 1 year by mammographic and physical examination. Ten patients were lost to follow-up. Of the remaining 101 patients, 98 (97%) had stable mammograms and normal physical examinations. Three patients (3.9%) required subsequent NLB due to progression of the mammographic lesion. Two cases were histologically benign, and 1 patient had ductal carcinoma in situ adjacent to the previous SCB biopsy site. An additional patient underwent NLB for a new radiographic abnormality at a separate location in the ipsilateral breast, which was invasive ductal carcinoma. SCB appears to be an effective alternative to NLB for the majority of patients deemed eligible. Careful mammographic follow-up is warranted for these patients given the small but real possibility of sampling error.

Original languageEnglish (US)
Pages (from-to)1124-1127
Number of pages4
JournalAmerican Surgeon
Volume63
Issue number12
StatePublished - Dec 12 1997
Externally publishedYes

Fingerprint

Breast
Biopsy
Needle Biopsy
Carcinoma, Intraductal, Noninfiltrating
Selection Bias
Physical Examination
Ductal Carcinoma
Lost to Follow-Up
Histology
Costs and Cost Analysis

ASJC Scopus subject areas

  • Surgery

Cite this

Pitre, B., Baron, P. L., Baron, L. F., O'Brien, P. H., & Cole, D. J. (1997). Stereotactic core biopsy of the breast: Results of one-year follow-up of 101 patients. American Surgeon, 63(12), 1124-1127.

Stereotactic core biopsy of the breast : Results of one-year follow-up of 101 patients. / Pitre, Brian; Baron, Paul L.; Baron, Lisa F.; O'Brien, Paul H.; Cole, David J.

In: American Surgeon, Vol. 63, No. 12, 12.12.1997, p. 1124-1127.

Research output: Contribution to journalArticle

Pitre, B, Baron, PL, Baron, LF, O'Brien, PH & Cole, DJ 1997, 'Stereotactic core biopsy of the breast: Results of one-year follow-up of 101 patients', American Surgeon, vol. 63, no. 12, pp. 1124-1127.
Pitre, Brian ; Baron, Paul L. ; Baron, Lisa F. ; O'Brien, Paul H. ; Cole, David J. / Stereotactic core biopsy of the breast : Results of one-year follow-up of 101 patients. In: American Surgeon. 1997 ; Vol. 63, No. 12. pp. 1124-1127.
@article{8e62bc6cc64f4b23811cfd4bf704c3da,
title = "Stereotactic core biopsy of the breast: Results of one-year follow-up of 101 patients",
abstract = "Stereotactic core biopsy (SCB) is being used as a cost-effective alternative to needle localized biopsy (NLB). However, an area of concern is the potential for sampling error, with sparse surgical data available concerning follow-up and failure rates. We therefore reviewed our results in patients undergoing SCB for mammographically detected breast abnormalities. Between January 1994 and February 1995, 128 patients underwent SCB. Average age was 56.4 years. Nine patients (7.0{\%}) had histologic evidence of malignancy, with 111 (86.7{\%}) benign diagnoses requiring no further initial intervention. Eight patients (6.3{\%}) proceeded directly to NLB, five because of technical failure of SCB and three because of suspicious initial histology. One of the latter patients had ductal carcinoma in situ. The remaining 111 SCB patients were evaluated at 6 months and 1 year by mammographic and physical examination. Ten patients were lost to follow-up. Of the remaining 101 patients, 98 (97{\%}) had stable mammograms and normal physical examinations. Three patients (3.9{\%}) required subsequent NLB due to progression of the mammographic lesion. Two cases were histologically benign, and 1 patient had ductal carcinoma in situ adjacent to the previous SCB biopsy site. An additional patient underwent NLB for a new radiographic abnormality at a separate location in the ipsilateral breast, which was invasive ductal carcinoma. SCB appears to be an effective alternative to NLB for the majority of patients deemed eligible. Careful mammographic follow-up is warranted for these patients given the small but real possibility of sampling error.",
author = "Brian Pitre and Baron, {Paul L.} and Baron, {Lisa F.} and O'Brien, {Paul H.} and Cole, {David J.}",
year = "1997",
month = "12",
day = "12",
language = "English (US)",
volume = "63",
pages = "1124--1127",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "12",

}

TY - JOUR

T1 - Stereotactic core biopsy of the breast

T2 - Results of one-year follow-up of 101 patients

AU - Pitre, Brian

AU - Baron, Paul L.

AU - Baron, Lisa F.

AU - O'Brien, Paul H.

AU - Cole, David J.

PY - 1997/12/12

Y1 - 1997/12/12

N2 - Stereotactic core biopsy (SCB) is being used as a cost-effective alternative to needle localized biopsy (NLB). However, an area of concern is the potential for sampling error, with sparse surgical data available concerning follow-up and failure rates. We therefore reviewed our results in patients undergoing SCB for mammographically detected breast abnormalities. Between January 1994 and February 1995, 128 patients underwent SCB. Average age was 56.4 years. Nine patients (7.0%) had histologic evidence of malignancy, with 111 (86.7%) benign diagnoses requiring no further initial intervention. Eight patients (6.3%) proceeded directly to NLB, five because of technical failure of SCB and three because of suspicious initial histology. One of the latter patients had ductal carcinoma in situ. The remaining 111 SCB patients were evaluated at 6 months and 1 year by mammographic and physical examination. Ten patients were lost to follow-up. Of the remaining 101 patients, 98 (97%) had stable mammograms and normal physical examinations. Three patients (3.9%) required subsequent NLB due to progression of the mammographic lesion. Two cases were histologically benign, and 1 patient had ductal carcinoma in situ adjacent to the previous SCB biopsy site. An additional patient underwent NLB for a new radiographic abnormality at a separate location in the ipsilateral breast, which was invasive ductal carcinoma. SCB appears to be an effective alternative to NLB for the majority of patients deemed eligible. Careful mammographic follow-up is warranted for these patients given the small but real possibility of sampling error.

AB - Stereotactic core biopsy (SCB) is being used as a cost-effective alternative to needle localized biopsy (NLB). However, an area of concern is the potential for sampling error, with sparse surgical data available concerning follow-up and failure rates. We therefore reviewed our results in patients undergoing SCB for mammographically detected breast abnormalities. Between January 1994 and February 1995, 128 patients underwent SCB. Average age was 56.4 years. Nine patients (7.0%) had histologic evidence of malignancy, with 111 (86.7%) benign diagnoses requiring no further initial intervention. Eight patients (6.3%) proceeded directly to NLB, five because of technical failure of SCB and three because of suspicious initial histology. One of the latter patients had ductal carcinoma in situ. The remaining 111 SCB patients were evaluated at 6 months and 1 year by mammographic and physical examination. Ten patients were lost to follow-up. Of the remaining 101 patients, 98 (97%) had stable mammograms and normal physical examinations. Three patients (3.9%) required subsequent NLB due to progression of the mammographic lesion. Two cases were histologically benign, and 1 patient had ductal carcinoma in situ adjacent to the previous SCB biopsy site. An additional patient underwent NLB for a new radiographic abnormality at a separate location in the ipsilateral breast, which was invasive ductal carcinoma. SCB appears to be an effective alternative to NLB for the majority of patients deemed eligible. Careful mammographic follow-up is warranted for these patients given the small but real possibility of sampling error.

UR - http://www.scopus.com/inward/record.url?scp=0030731529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030731529&partnerID=8YFLogxK

M3 - Article

C2 - 9393264

AN - SCOPUS:0030731529

VL - 63

SP - 1124

EP - 1127

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 12

ER -